Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder
2023; Lippincott Williams & Wilkins; Volume: 101; Issue: 4 Linguagem: Inglês
10.1212/wnl.0000000000207443
ISSN1526-632X
AutoresStanislas Demuth, Nicolas Collongues, Bertrand Audoin, Xavier Ayrignac, Bertrand Bourre, Jonathan Ciron, Mikaël Cohen, Romain Deschamps, Françoise Durand‐Dubief, Élisabeth Maillart, Caroline Papeix, Aurélie Ruet, Hélène Zéphir, Romain Marignier, de Sèze,
Tópico(s)Neurogenesis and neuroplasticity mechanisms
ResumoExit strategies such as de-escalations have not been evaluated for rituximab in patients with neuromyelitis optica spectrum disorder (NMOSD). We hypothesized that they are associated with disease reactivations and aimed to estimate this risk.
Referência(s)